MedCity News September 18, 2024
By acquiring Dermavant, Organon gets Vtama, a drug approved for treating plaque psoriasis. An FDA decision for the topical cream in atopic dermatitis is expected by the end of 2024.
Organon is broadening its presence in dermatology with a deal to acquire Dermavant, a company whose main asset is a commercialized plaque psoriasis drug that could soon expand its approval to include an even more prevalent inflammatory skin disorder.
Under terms of the agreement announced Wednesday, Organon could pay out as much as $1.2 billion for Dermavant, a subsidiary of Roivant Sciences. But Roivant is getting just $175 million up front. The rest of the deal is heavily weighted with milestones, similar to deal structures of other Organon transactions. The...
Today's Sponsors
Today's Sponsor